ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma

Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC. In the current study, we identified that ABCC5 is a critical regulator and a promising therapeutic ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wenbin, Chen, Kunling, Lu, Yishi, Zhang, Donghui, Cheng, Yuan, Li, Liuran, Huang, Weimei, He, Guolin, Liao, Hangyu, Cai, Lei, Tang, Yujun, Zhao, Liang, Pan, Mingxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591347/
https://www.ncbi.nlm.nih.gov/pubmed/34768109
http://dx.doi.org/10.1016/j.neo.2021.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591347/
https://www.ncbi.nlm.nih.gov/pubmed/34768109
http://dx.doi.org/10.1016/j.neo.2021.11.002

Ejemplares similares